• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Worsening Neurological Symptoms in an Older Man With History of Rectal Cancer

Article

A 65-year-old man, who was lost to follow-up after abdominal-perineal resection for rectal adenocarcinoma 9 months earlier, presents with progressively worsening neurological symptoms, including bilateral hearing loss, dizziness, gait disturbance, ataxia, and blindness in the right eye.

A 65-year-old man, who was lost to follow-up after abdominal-perineal resection for rectal adenocarcinoma 9 months earlier, presents with progressively worsening neurological symptoms, including bilateral hearing loss, dizziness, gait disturbance, ataxia, and blindness in the right eye.

Audiometric evaluation demonstrates profound hearing loss with no identifiable thresholds in all frequencies, absent reflexes, and absent otoacoustic emissions.

Findings on a CT scan of the head are unremarkable. MRI scans of the brain with gadolinium reveal enhancement along the meningeal surfaces of the right optic nerve and to a lesser degree of the left optic nerve (A), and expanded cranial nerves VII and VIII bilaterally (B). No evidence of hydrocephalus, intraparenchymal mass, or stroke is present.

Based on the clinical picture and MRI findings, what would you include in the differential?

Answer on Next Page

WORKING THROUGH THE DIFFERENTIAL

Initially, Cogan syndrome (a rare autoimmune-mediated rheumatic disorder of interstitial keratitis that develops shortly after recovery from an otherwise unremarkable respiratory infection) was suspected. Other conditions in the differential diagnosis included neurosarcoidosis, multiple sclerosis, autoimmune vasculitis, lupus, Wegener granulomatosis, antiphospholipid syndrome, tuberculosis, syphilis, Lyme disease, and malignancy. The patient was empirically treated with aspirin, clopidogrel, enoxaparin, methylprednisolone, cyclophosphamide, and piperacillin/tazobactam.

 

Results of an extensive autoimmune laboratory evaluation (VDRL test, serum protein electrophoresis, Brucella antibody, antineutrophil cytoplasmic antibody, perinuclear antineutrophil cytoplasmic antibody, antinuclear antibody, anti–smooth muscle antibody, C3, C4, Purkinje antibody, Sjogren antibody, SCL 70 for systemic sclerosis, anti-RNP antibody for mixed connective-tissue disease, cryoglobulin, anti-DNA antibody, rheumatoid factor, rapid plasma reagin, mixing studies, and anticardiolipin antibody) were normal. Cerebrospinal fluid (CSF) studies showed 156 nucleated cells/mL in tube 1, 138 nucleated cells/mL in tube 4, 85% macrophages, 15% lymphocytes, a glucose level of 27 mg/dL (range, 40 to 60 mg/dL), and protein level greater than 300 mg/dL; results of acid-fast bacillus smear, Gram stain, and cytology examination were negative.


Figure – Histological evaluation of the biopsy specimen revealed cytokeratin and mucicarmine, consistent with a metastatic tumor of GI origin.

 

After a week without clinical improvement, empirical therapy for tuberculosis and syphilis was initiated. A second lumbar puncture done a week later was positive for atypical cells. A subsequent biopsy of the cerebellopontine angle was positive for signet ring cell adenocarcinoma (Figure).

 

Consequently, cyclophosphamide, methylprednisolone, and the antibiotics were discontinued. The patient received radiotherapy followed by intrathecal chemotherapy.

 

DIAGNOSIS:

Metastatic rectal cancer presenting as leptomeningeal carcinomatosis

The most common presenting features of leptomeningeal carcinomatosis are cranial nerve palsies (75%), headache (66%), cerebral disturbances (66%), spinal nerve dysfunction presenting as either autonomic dysfunction or sensory deficits (60%), mental changes (45%), and limb weakness (44%).1 The most commonly involved cranial nerves are III, IV, VI, and VII.1

 

The diagnosis is based on CSF examination and radiological investigation, mainly with MRI.2 Lumbar puncture for CSF cytology remains the standard diagnostic procedure; demonstration of malignant cells in the CSF is the gold standard.1 A positive CSF cytology is found in 30% to 40% of cases on the initial lumbar puncture and in 80% to 90% of cases after 3 attempts.1 Increased CSF opening pressure is found in 50% of patients and depends on the extent of the leptomeningeal involvement.1 Elevated CSF protein levels and low glucose levels are observed in about 75% and 40% of the cases, respectively.1

 

Gadolinium-enhanced MRI is more sensitive than CT in detecting leptomeningeal metastases: the sensitivity is nearly 70% for MRI compared with about 30% for CT.1 The most common MRI findings consist of typical nodules in subarachnoid and parenchymal regions, parenchymal volume loss, and sulcal/dural enhancement. The differential diagnosis should include infectious causes, inflammatory diseases, trauma, and subdural hematomas.1

References:

REFERENCES:1. Pavlidis N. The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann Oncol. 2004;15(suppl 4):iv285-iv291.
2. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38:51-57.
 

Recent Videos
Infectious disease specialist talks about COVID-19 vaccine development
COVID 19 impact on healthcare provider mental health
Physician mental health expert discusses impact of COVID-19 on health care workers
Related Content
© 2024 MJH Life Sciences

All rights reserved.